Teddington, UK 5/1/18—LGC has acquired BioAutomation, a manufacturer of DNA synthesizers, for an undisclosed amount. “The acquisition will allow us to provide our oligonucleotide reagent customers a complete and fully supported oligo synthesis solution, as well as helping to drive advancements in automation for all aspects of our oligo manufacturing processes,” stated Brian Kim, president and managing director, Genomics division, LGC. “BioAutomation’s MerMade brand instruments are the premium synthesizers on the market with a significant installed base.” Based in Irving, Texas, BioAutomation has 17 employees. Its MerMade offering consists of eight instruments that can synthesize 4–192 oligos at the same time at scales of 50 nmol–200 µmol. The company also sells consumables. The acquisition is the latest addition to LGC’s nucleic acid chemistry business, which has been built through the purchases of Bioresearch (see IBO 7/31/17), LINK Technologies (see IBO 7/15/17) and Prime Synthesis (see IBO 11/30/16). This latest purchase adds lab instrumentation to a LGC’s consumables and manufacturing capabilities.